Retinal degenerative diseases, including age-related macular degeneration (AMD) and diabetic retinopathy, affect hundreds of millions worldwide, with AMD projected to affect 288 million people by 2040. Clinical management of AMD typically involves repeated intravitreal injections of antivascular endothelial growth factor (anti-VEGF) agents for the wet form, and oral supplementation with antioxidant vitamins and minerals for the dry form. This evidence concerns the gene VEGFA and age-related macular degeneration.